To confirm that IL‐32 is the downstream effector of YY1‐mediated PC effects on EGFR‐mutated cancer cell sensitivity to TKI, we exposed these cells to CM from YY1‐depleted PCs in the presence of TKI drugs, with or without IL32 treatment. The gene discussed is EGFR; the disease is cancer.